UPSC Drug Inspector key terms

The fraction of an administered dose of unchanged drug that reaches systemic circulation, expressed as a percentage or as rate and extent of absorption compared against an intravenous reference standard.

The absence of a significant difference in the rate and extent of absorption between two pharmaceutically equivalent products, typically assessed by comparing AUC and Cmax within accepted confidence limits.

Presystemic biotransformation of an orally administered drug in gut wall or liver before it enters systemic circulation, reducing oral bioavailability relative to intravenous dosing.

A pharmacologically inactive chemical derivative that must undergo enzymatic or chemical conversion in the body to release the active drug, often used to improve absorption, stability, or targeting.

A ratio comparing the dose producing toxic effects with the dose producing therapeutic effect; a narrow index means small dose changes can cause toxicity and warrants careful monitoring.

A ligand that binds a receptor and activates it to produce a biological response, possessing both affinity for the binding site and intrinsic efficacy.

A ligand that binds a receptor with affinity but without intrinsic efficacy, blocking or reducing the response produced by agonists; may be competitive or non-competitive.

A ligand that binds and activates a receptor but produces a submaximal response even at full occupancy, and can act as a functional antagonist when competing with a full agonist.

The time required for the plasma concentration or amount of drug in the body to decline by half, governing dosing interval selection and time to reach steady state.

A theoretical volume relating the amount of drug in the body to its plasma concentration; high values indicate extensive tissue distribution rather than confinement to plasma.

The volume of plasma from which a drug is completely removed per unit time by all eliminating organs, determining the maintenance dose rate needed for a target steady-state concentration.

A category of prescription medicines under the Drugs and Cosmetics Rules that may be sold only on the written prescription of a registered medical practitioner, with specific labelling and record-keeping duties.

A class of drugs requiring stricter control than Schedule H, including maintenance of separate registers, prescription retention, and licensing conditions intended to curb misuse and diversion.

Medicines that must carry a caution label warning that they should be used only under medical supervision, reflecting their potential for harmful effects if self-administered.

The part of the Drugs and Cosmetics Rules prescribing good manufacturing practice requirements, including premises, plant, equipment, and quality control provisions for pharmaceutical manufacture.

Current good manufacturing practice: the set of regulatory standards ensuring products are consistently produced and controlled according to quality standards appropriate to their intended use.

Documented evidence providing a high degree of assurance that a process, method, or system consistently produces results meeting predetermined specifications and quality attributes.

The documented verification that equipment, facilities, or utilities are correctly installed, operate as intended, and perform consistently, usually staged as design, installation, operation, and performance qualification.

Climatic zone classifications defined by long-term temperature and humidity conditions used to design stability studies; India falls in Zone IVb with hot and very humid conditions.

Deliberate exposure of a drug substance or product to stress conditions such as heat, light, acid, base, and oxidation to identify degradation pathways and demonstrate analytical method specificity.

The period during which a pharmaceutical product, stored under labelled conditions, is expected to remain within its approved specification for potency, purity, and appearance.

An official compendium of drug standards, monographs, and analytical methods recognized by law in a jurisdiction, providing legally enforceable specifications for identity, purity, and strength.

A highly characterized, authenticated material used as a benchmark in analytical testing, against which samples are compared for identity, potency, or impurity content.

A formal pharmacopoeial entry for a drug or excipient stating its definition, characters, identification tests, assay limits, and storage requirements that must be met by the article.

A naturally occurring nitrogen-containing basic organic compound found in plants, often pharmacologically potent, such as morphine, quinine, and atropine.

A plant constituent in which a sugar moiety is linked to a non-sugar aglycone; hydrolysis releases the aglycone, which often carries the principal pharmacological activity.

A polyphenolic plant constituent that binds and precipitates proteins, producing astringent effects and serving as a qualitative test marker in plant drug identification.

Any validated process that destroys or removes all viable microorganisms, including bacterial spores, from an article or environment.

The probability that a single unit of a sterilized product is non-sterile, conventionally required to be no greater than one in a million for terminally sterilized products.

A validated process that destroys or removes pyrogens such as bacterial endotoxin from glassware or heat-stable materials, commonly by dry heat at high temperature.

A limulus amoebocyte lysate based assay used to detect or quantify endotoxin from gram-negative bacteria in parenteral products, medical devices, and raw materials.

A spherical vesicle of one or more phospholipid bilayers enclosing an aqueous core, used to encapsulate drugs, alter biodistribution, and reduce systemic toxicity.

A non-ionic surfactant based vesicle analogous to a liposome, offering greater chemical stability and lower cost than phospholipid vesicles for drug delivery.

A solid colloidal carrier with dimensions typically between one and one hundred nanometres, engineered to solubilize drugs, control release, or enable targeted delivery.

An antibody produced from a single clone of cells, binding one specific epitope, widely used as a therapeutic biologic with defined target specificity.

A biologic product highly similar to an already licensed reference biologic in safety, purity, and potency, approved on the basis of comparability rather than full clinical trials.

Techniques for inserting a foreign gene into a host cell so it expresses the encoded protein, used to manufacture insulin, interferons, and other therapeutic proteins.

An in vitro test measuring the rate at which a drug dissolves from a dosage form into a specified medium under controlled conditions, serving as a surrogate for product performance.